JP2011520868A - 胃酸分泌を阻害するための組成物および方法 - Google Patents

胃酸分泌を阻害するための組成物および方法 Download PDF

Info

Publication number
JP2011520868A
JP2011520868A JP2011509043A JP2011509043A JP2011520868A JP 2011520868 A JP2011520868 A JP 2011520868A JP 2011509043 A JP2011509043 A JP 2011509043A JP 2011509043 A JP2011509043 A JP 2011509043A JP 2011520868 A JP2011520868 A JP 2011520868A
Authority
JP
Japan
Prior art keywords
ppi
composition
stomach
low molecular
succinic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011509043A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011520868A5 (https=
Inventor
アレクセイ コスタディノフ，
タル アタロット，
ミハエル ナヴェー，
Original Assignee
ヴェクタ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴェクタ リミテッド filed Critical ヴェクタ リミテッド
Publication of JP2011520868A publication Critical patent/JP2011520868A/ja
Publication of JP2011520868A5 publication Critical patent/JP2011520868A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011509043A 2008-05-14 2009-05-14 胃酸分泌を阻害するための組成物および方法 Withdrawn JP2011520868A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/120,599 2008-05-14
US12/120,599 US7981908B2 (en) 2005-05-11 2008-05-14 Compositions and methods for inhibiting gastric acid secretion
PCT/IB2009/006176 WO2009138884A2 (en) 2008-05-14 2009-05-14 Compositions and methods for inhibiting gastric acid secretion

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014194754A Division JP2014240435A (ja) 2008-05-14 2014-09-25 胃酸分泌を阻害するための組成物および方法

Publications (2)

Publication Number Publication Date
JP2011520868A true JP2011520868A (ja) 2011-07-21
JP2011520868A5 JP2011520868A5 (https=) 2013-04-25

Family

ID=41319115

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011509043A Withdrawn JP2011520868A (ja) 2008-05-14 2009-05-14 胃酸分泌を阻害するための組成物および方法
JP2014194754A Pending JP2014240435A (ja) 2008-05-14 2014-09-25 胃酸分泌を阻害するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014194754A Pending JP2014240435A (ja) 2008-05-14 2014-09-25 胃酸分泌を阻害するための組成物および方法

Country Status (7)

Country Link
US (3) US7981908B2 (https=)
EP (1) EP2296470A4 (https=)
JP (2) JP2011520868A (https=)
AU (1) AU2009247712C1 (https=)
CA (1) CA2725437C (https=)
IL (1) IL209296A0 (https=)
WO (1) WO2009138884A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080020041A1 (en) * 2004-10-19 2008-01-24 Ayres James W Enteric Coated Compositions that Release Active Ingredient(s) in Gastric Fluid and Intestinal Fluid
US7981908B2 (en) * 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
PL2046334T3 (pl) * 2006-07-25 2015-02-27 Vecta Ltd Kompozycje i sposoby hamowania wydzielania kwasów żołądkowych z wykorzystaniem pochodnych małych kwasów dikarboksylowych w połączeniu z PPI
ES2744406T3 (es) * 2013-02-13 2020-02-25 Redhill Biopharma Ltd Composiciones farmacéuticas para el tratamiento de helicobacter pylori
CN114315750B (zh) * 2020-09-29 2024-05-10 鲁南制药集团股份有限公司 一种莫沙必利-丁二酸共晶

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60193917A (ja) * 1984-03-14 1985-10-02 R P Shiila- Kk 多重構造軟カプセル剤
JP2005528383A (ja) * 2002-04-10 2005-09-22 ミラー，フレッド，エイチ． 多重相・複数コンパートメントカプセルシステム
WO2006120500A1 (en) * 2005-05-11 2006-11-16 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
JP2007532677A (ja) * 2004-04-16 2007-11-15 サンタラス インコーポレイティッド プロトンポンプ阻害剤、緩衝剤、および運動促進薬の組み合わせ
WO2008012621A2 (en) * 2006-07-25 2008-01-31 Vecta, Ltd. Compositions and meth0ds for inhibiting gastric acide secretion using derivatives of small dicarboxylic acids in combination with ppi

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2046334A (en) 1933-02-25 1936-07-07 Stay On Mfg Company Utensil
US2343011A (en) 1941-07-11 1944-02-29 Huppert Oskar Thio-protein plastic
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
JPS59104326A (ja) * 1982-12-04 1984-06-16 Toyo Jozo Co Ltd マクロライド抗生物質の安定な経口用製剤および安定化法
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
JPS6194717A (ja) * 1984-10-17 1986-05-13 Takara Co Ltd 合成樹脂製人形等の成形方法およびその装置
US4767627A (en) 1985-05-29 1988-08-30 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
US5238686A (en) * 1986-03-27 1993-08-24 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB8621425D0 (en) 1986-09-05 1986-10-15 Smith Kline French Lab Compounds
IL88507A (en) 1987-12-03 1993-02-21 Smithkline Beckman Intercredit 2,4-diaminoquinazolines, process for their preparation and pharmaceutical compositions comprising them
SE8804629D0 (sv) 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
JP2656338B2 (ja) 1989-01-31 1997-09-24 日東電工株式会社 口腔粘膜貼付製剤
CA2015981A1 (en) 1989-05-10 1990-11-10 Thomas H. Brown Compounds
US5048353A (en) 1990-03-01 1991-09-17 Beloit Corporation Method and apparatus for roll profile measurement
JPH03287103A (ja) 1990-04-02 1991-12-17 Seiko Epson Corp カラーフィルターの形成法
SE9002206D0 (sv) 1990-06-20 1990-06-20 Haessle Ab New compounds
DE69131627T2 (de) 1990-06-20 2000-04-27 Astra Ab Soedertaelje Dialkoxypyridinylbenzimidazolderivate, verfahren zur herstellung und ihre pharmazeutische verwendung
JPH06510547A (ja) 1992-07-06 1994-11-24 コミスサローバ，イリナ　アレクセエフナ 抗アルコール活性を有し、エネルギー代謝と胃粘膜の酸を生成し分泌する機能とを刺激し、放射能防御活性と抗コレラ活性を有する医薬組成物
US7795239B2 (en) 1992-07-27 2010-09-14 Mueller Medical International LLC Saccharide compositions and method of use
SE9301489D0 (sv) 1993-04-30 1993-04-30 Ab Astra Veterinary composition
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302396D0 (sv) 1993-07-09 1993-07-09 Ab Astra A novel compound form
JP2896532B2 (ja) 1994-08-13 1999-05-31 ユーハン コーポレーション 新規なピリミジン誘導体およびその製造方法
ES2094694B1 (es) * 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
US6132768A (en) * 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
SE512835C2 (sv) 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
US5677302A (en) 1996-02-26 1997-10-14 Apotex Inc. Thiadiazole compounds useful as proton pump inhibitors
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US5800832A (en) 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
SE9702533D0 (sv) * 1997-07-01 1997-07-01 Astra Ab New oral formulation
US6296876B1 (en) 1997-10-06 2001-10-02 Isa Odidi Pharmaceutical formulations for acid labile substances
ATE500815T1 (de) 1997-12-08 2011-03-15 Dietrich Rango Neue suppositoriumsform mit säureempfindlichem wirkstoff
IT1296980B1 (it) * 1997-12-17 1999-08-03 Istituto Pirri S R L Capsula doppia come forma farmaceutica per la somministrazione di principi attivi in terapie multiple
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
CA2331834A1 (en) 1998-06-18 1999-12-23 Michal Y. Chowers Pharmaceutical compositions for the treatment of helicobacter pylori-associated disorders
SE9902386D0 (sv) 1999-06-22 1999-06-22 Astra Ab New formulation
US6228400B1 (en) 1999-09-28 2001-05-08 Carlsbad Technology, Inc. Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
US7365047B1 (en) 1999-09-28 2008-04-29 The Regents Of The University Of California Use of pentagastrin to inhibit gastric acid secretion or as a diuretic
US7429599B2 (en) 2000-12-06 2008-09-30 Signal Pharmaceuticals, Llc Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
US20030049204A1 (en) 2001-04-24 2003-03-13 Mcgill University Individualization of therapy with gastroesophageal reflux disease agents
US20030235628A1 (en) * 2001-09-19 2003-12-25 Rajneesh Taneja Methods and pharmaceutical formulations for protecting pharmaceutical compounds from acidic environments
US20030175360A1 (en) * 2002-02-22 2003-09-18 Renzo Luzzatti Symptomatic relief of gastrointestinal disorders
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
WO2003103592A2 (en) 2002-06-06 2003-12-18 University Of Washington Covalent conjugates between artemisinin-related endoperoxides and iron-carrying proteins and methods of use
ES2578252T3 (es) * 2002-09-24 2016-07-22 Gumlink A/S Goma de mascar que comprende al menos dos polímeros biodegradables diferentes
IL152289A0 (en) 2002-10-14 2003-05-29 Vectabiotics Ltd Method and composition for inhibiting h.pylori infection in a mammalian tissue
WO2005020879A2 (en) 2003-08-27 2005-03-10 Vecta Ltd. Compositions for treating pathologies that necessitate suppression of gastric acid secretion
US20060135406A1 (en) 2002-10-14 2006-06-22 Sabina Glozman Compositions and methods for treating pathologies that necessitate suppression of gastric acid secretion
US20060127489A1 (en) * 2002-10-24 2006-06-15 Michael Crothers Targeted delivery
US6866653B2 (en) * 2002-10-31 2005-03-15 Kyongtae T. Bae Method and apparatus for sequential delivery of multiple injectable substances stored in a prefilled syringe
GB2394895A (en) 2002-11-06 2004-05-12 Cipla Ltd Proton pump inhibitor composition in paste form
US20040248942A1 (en) 2003-02-20 2004-12-09 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
WO2004112756A1 (en) 2003-06-26 2004-12-29 Isa Odidi Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
WO2005020954A2 (en) 2003-09-03 2005-03-10 Agi Therapeutics Limited Proton pump inhibitor formulations, and methods of preparing and using such formulations
US7211568B2 (en) 2003-12-18 2007-05-01 Kosan Biosciences Incorporated 9-Desoxoerythromycin compounds as prokinetic agents
RS20050796A (sr) 2004-01-06 2007-08-03 Panacea Biotec Ltd., Farmaceutske smeše koje sadrže inhibitor protonske pumpe i prokinetičko sredstvo
US20050181052A1 (en) 2004-02-17 2005-08-18 Patel Satishkumar A. Lansoprazole microtablets
BRPI0516308A2 (pt) 2004-10-04 2010-06-15 Qlt Usa Inc composição fluida, métodos de tratamento de uma doença ou disfunção, métodos de liberação local ou sistêmica de um agente biológico, implantes, método de formação de um implante, kit de agente biológico e usos de uma composição fluida
LT2801354T (lt) 2004-10-08 2017-06-26 Forward Pharma A/S Kontroliuojamo atpalaidavimo farmacinės kompozicijos, apimančios fumaro rūgšties esterį
CA2598696A1 (en) * 2005-02-23 2006-08-31 Surmodics, Inc. Implantable medical articles having laminin coatings and methods of use
US7981908B2 (en) * 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
PL226695B1 (pl) 2006-07-03 2017-08-31 Danuta Kruszewska Środek do zastosowania w zapobieganiu i/lub hamowaniu kolonizacji Helicobacter pylori, zastosowanie soli kwasu alfa‑ketoglutarowego z metalami alkalicznymi i ziem alkalicznych do wytwarzania środka leczniczego oraz dodatku do żywności do zapobiegania i/lub hamowania kolonizacji Helicobacter pylori

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60193917A (ja) * 1984-03-14 1985-10-02 R P Shiila- Kk 多重構造軟カプセル剤
JP2005528383A (ja) * 2002-04-10 2005-09-22 ミラー，フレッド，エイチ． 多重相・複数コンパートメントカプセルシステム
JP2007532677A (ja) * 2004-04-16 2007-11-15 サンタラス インコーポレイティッド プロトンポンプ阻害剤、緩衝剤、および運動促進薬の組み合わせ
WO2006120500A1 (en) * 2005-05-11 2006-11-16 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
WO2008012621A2 (en) * 2006-07-25 2008-01-31 Vecta, Ltd. Compositions and meth0ds for inhibiting gastric acide secretion using derivatives of small dicarboxylic acids in combination with ppi

Also Published As

Publication number Publication date
IL209296A0 (en) 2011-01-31
US9132082B2 (en) 2015-09-15
US20080248109A1 (en) 2008-10-09
AU2009247712C1 (en) 2015-01-22
AU2009247712A1 (en) 2009-11-19
WO2009138884A3 (en) 2010-01-28
CA2725437A1 (en) 2009-11-19
EP2296470A4 (en) 2013-05-22
US20110111039A1 (en) 2011-05-12
EP2296470A2 (en) 2011-03-23
US20110250268A1 (en) 2011-10-13
US7981908B2 (en) 2011-07-19
AU2009247712B2 (en) 2014-08-28
JP2014240435A (ja) 2014-12-25
CA2725437C (en) 2016-02-09
WO2009138884A2 (en) 2009-11-19
US9370481B2 (en) 2016-06-21

Similar Documents

Publication Publication Date Title
US9278080B2 (en) Compositions and methods for inhibiting gastric acid secretion
JP2014240435A (ja) 胃酸分泌を阻害するための組成物および方法
US9233092B2 (en) Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with PPI
JP2007503427A (ja) 胃酸分泌の抑制を必要とする病状を治療するための組成物
CN101500553B (zh) 联合使用小分子二羧酸的衍生物与ppi用于抑制胃酸分泌的组合物和方法
JP2013006843A (ja) 胃酸分泌
HK1120421B (en) Compositions and their preparation methods for inhibiting gastric acid secretion

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130924

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130927

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131211

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140122

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140925

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20141118

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20141212

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20141222